Milestone Pharmaceuticals/$MIST
1D1W1MYTD1Y5YMAX
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
- Ticker
- $MIST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 38
- Headquarters
- Montreal, Canada
- Website
- www.milestonepharma.com
MIST Metrics
BasicAdvanced
$163M
-
-$0.71
0.98
-
Price and volume
Market cap
$163M
Beta
0.98
52-week high
$3.06
52-week low
$1.00
Average daily volume
1.5M
Financial strength
Current ratio
8.129
Quick ratio
7.869
Long term debt to equity
774.849
Total debt to equity
778.527
Interest coverage (TTM)
-7.25%
Profitability
EBITDA (TTM)
-78.207
Gross margin (TTM)
98.04%
Net profit margin (TTM)
-3,585.62%
Operating margin (TTM)
-3,345.24%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-42.78%
Return on equity (TTM)
-35,522.62%
Valuation
Price to revenue (TTM)
58.409
Price to book
8.97
Price to tangible book (TTM)
8.97
Price to free cash flow (TTM)
-2.22
Free cash flow yield (TTM)
-45.05%
Free cash flow per share (TTM)
-0.523
Growth
Earnings per share change (TTM)
-14.98%
3-year revenue growth (CAGR)
-26.91%
3-year earnings per share growth (CAGR)
-19.66%
What the Analysts think about MIST
Analyst ratings (Buy, Hold, Sell) for Milestone Pharmaceuticals stock.
MIST Financial Performance
Revenues and expenses
MIST Earnings Performance
Company profitability
MIST News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.